Kuros reports publication of MagnetOs preclinical data demonstrating superiority to market-leading synthetic bone grafts in spinal fusion
Schlieren (Zurich), Switzerland, January 30, 2020 – Kuros Biosciences (SIX: KURN) today announced the publication of data from a clinically-relevant preclinical model comparing MagnetOs with autologous bone, Vitoss® BA2X (Stryker Corp.) and Novabone Putty® (Novabone Products, LLC) in instrumented posterolateral spinal fusion in sheep.
Utilizing multiple assessments for fusion, the study concluded that MagnetOs is an appropriate alternative to autograft when used as a standalone graft and was significantly better at achieving uniform, solid and stable fusions than the comparator products.
The publication, which is entitled “MagnetOs, Vitoss & Novabone in a multi-endpoint study of posterolateral fusion: A true fusion or not?”, has been accepted for publication by Clinical Spine Surgery and is available online as an open access paper via the following link:
Joost de Bruijn, Chief Executive Officer of Kuros, said: “This robust and clinically-relevant large animal study confirms that MagnetOs really is different from other synthetic grafts on the market. Our early clinical feedback from leading spine surgeons is consistent with this dataset. Kuros has further committed to conducting at least ten post-market clinical studies to validate these encouraging outcomes.”
Professor Bill Walsh, University of New South Wales, Australia, who was principal investigator of the study and presented the data at this year’s North American Spine Society annual meeting in Chicago last September said: “I’ve investigated many of the leading synthetic bone grafts in this model and, in my experience, MagnetOs leads to the most compelling fusion outcomes of all the grafts I’ve tested.”